A dose-finding study of CpG 7909 in previously treated chronic lymphocytic leukemia.

Trial Profile

A dose-finding study of CpG 7909 in previously treated chronic lymphocytic leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Agatolimod (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 15 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top